A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622
Latest Information Update: 12 Jun 2022
At a glance
- Drugs Mepolizumab (Primary)
- Indications Hypereosinophilic syndrome
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association
- 19 May 2021 Results presented at the 117th International Conference of the American Thoracic Society.
- 10 Jan 2020 Status changed from active, no longer recruiting to completed.